Roquefort Therapeutics (LON:COIL) Shares Down 10% – Here’s What Happened

Roquefort Therapeutics plc (LON:COIL)’s share price dropped 10% on Monday . The stock traded as low as GBX 10.10 and last traded at GBX 10.80. Approximately 782,783 shares traded hands during mid-day trading, an increase of 130% from the average daily volume of 339,970 shares. The stock had previously closed at GBX 12.

Roquefort Therapeutics Price Performance

The firm has a market capitalization of £44.81 million, a P/E ratio of -0.48 and a beta of 0.05. The company has a debt-to-equity ratio of 8.07, a quick ratio of 3.07 and a current ratio of 2.80. The firm has a 50-day moving average of GBX 9.13 and a 200-day moving average of GBX 11.34.

Roquefort Therapeutics (LON:COIL) last released its quarterly earnings data on Wednesday, May 6th. The company reported GBX (2.19) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 18.30%.

Roquefort Therapeutics Company Profile

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.